Table 1:
Patient demographics for the study. Table indicates patient gender, history, LMM assessment, time of diagnosis, location of the primary melanoma, other sites of metastases, BRAF mutational status and patient vital status at time of analysis.
| Patient # | Gender | Tumor History | LMM assessment (Clin; MRI; Cytology) | Age at DX of LMM | Location of Primary | Other metastatic sites | Genotype | Life status; LMM survival (mo) |
|---|---|---|---|---|---|---|---|---|
| 1 | F | Melanoma 2012; Brain Mets + LMM 2016 | Cyt+ | 34 | Right shoulder | Brain | BRAF V600E | Alive, 35+ |
| 2 | M | Melanoma 1976; Brain Mets + LMM 2017 | Cyt+; autosy confirm | 53 | Right cheek spitz nevus | Lung | BRAF V600E | Deceased; 4.2 |
| 3 | M | Uveal Melanoma + LMM | MRI+; Cyt+ | 65 | Left eye | Liver | GNAQ Q209P, SF3B1 R625C | Deceased; 0.5 |
| 4 | M | Melanoma 2013; Brain Mets + LMM 2017 | Clin+; MRI+ Cyt Atyp | 36 | Right chest | Brain, LN, Lung | BRAF V600E | Deceased; 4.4 |
| 5 | M | Melanoma 2013; Brain Mets + LMM 2017 | Cyt+; autopsy confirm | 39 | Right back | Brain, LN, Lung | BRAF V600E | Deceased; 2.1 |
| 6 | M | Melanoma 2014; Brain Mets + LMM 2016 | Clin+; MRI+; Cyt− | 72 | Left Shoulder | Skin, Liver, Bone | BRAF V600E | Deceased; 0.5 |
| 8 | M | Melanoma 2006; Brain Mets + LMM 2017 | Clin+; MRI+; Cyt+; autopsy confirm | 69 | Lower back | Brain, LN (also colon cancer) | BRAF V600E | Deceased; 1.2 |
| 9 | M | Melanoma 2010; LMM 2015 | Clin+; MRI+; Cyt suspicious | 64 | Right leg | LN | BRAF V600E | Deceased; 4.2 |